Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1522-1525

  Iwasaki, Tomoyuki ^a   Tomeno, Wataru ^b   Yoneda, Masato ^b   Inamori, Masahiko ^b   Shirakawa, Jun ^b   Imajo, Kento ^b   Kawashima, Keigo ^b   Terauchi, Yasuo ^b   Nakajima, Atsushi ^b  

^a Iwasaki Naika Clinic   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

DM; DPP 4 inhibitor; NAFLD; Sitagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; SITAGLIPTIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHESIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY LIVER; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; PYRAZINES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84865156862     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11689     Document Type: Article

References (21)

1. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, et al.: Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009; 122:443-453.
2. Ahrén B: Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3:365-372.
3. Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2001; 122:531-544.
4. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214:829-835.
5. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80:952-957.
6. Göke R, Fehmann HC, Linn T, et al.: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268:19650-19655.
7. Kim D, Wang L, Beconi M, et al.: (2R)-4-oxo-4-(3-(trifluoromethyl)-5,6- dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48:141-151.
8. Iwasaki T, Yoneda M, Inamori M, et al.: Sitagliptin as a novel treatment agent for nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepato-gastroenterol 2011; 58(112):Epub ahead of print.
9. Firneisz G, Varga T, Lengyel G, et al.: Serum dipeptidyl peptidases activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010; 5(8):e12226.
10. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
11. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123:1705-1725.
12. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053.
13. Angulo P: Non-alcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
14. Powell EE, Cooksley WG, Hanson R, et al.: The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
15. Yoshiike N, Lwin H: Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res 2005; 33:77-82.
16. Chitturi S, Abeygunasekera S, Farrell GC, et al.: NASH and insulin resistance: Insulin hyper secretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35:373-379.
17. Kawamura Y, Arase Y, Ikeda K, et al.: Diabetes enhances hepatocarcinogenesis in non-cirrhotic, interferon-treated hepatitis C patients. Am J med 2010; 123:951-956.
18. Migoya EM, Stevens CH, Bergman AJ, et al.: Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16:e165-170.
19. Vincent SH, Reed JR, Bergman AJ, et al.: Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor (14C) sitagliptin in humans. Drug Metab Dispos 2007; 35:533-538.
20. Gupta NA, Mells J, Dunham RM, et al.: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51:1584-1592.
21. Ben-Shlomo S, Zvibel I, Shnell M, et al.: Glucagon-Like Peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2010; 54:1214-1223.